- Home
- ZYME vs DCOM Comparison
ZYME vs DCOM Comparison
Compare ZYME & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZYME | DCOM |
|---|---|---|
| Founded | 2003 | 1864 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2022 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ZYME | DCOM |
|---|---|---|
| Price | $28.10 | $40.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | $41.21 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 869.8K | 312.8K |
| Earning Date | 11-09-2026 | 10-20-2026 |
| Dividend Yield | N/A | ★ 2.44% |
| EPS Growth | 33.33 | ★ 329.09 |
| EPS | N/A | ★ 1.49 |
| Revenue | ★ $105,965,000.00 | $19,907,000.00 |
| Revenue This Year | $173.22 | $14.41 |
| Revenue Next Year | $35.07 | $10.39 |
| P/E Ratio | ★ N/A | $27.44 |
| Revenue Growth | ★ 38.87 | 19.03 |
| 52 Week Low | $16.00 | $25.63 |
| 52 Week High | $31.34 | $41.97 |
Technical Indicators
Market Signals| Indicator | ZYME | DCOM |
|---|---|---|
| Relative Strength Index (RSI) | 59.63 | 60.37 |
| Support Level | $22.04 | $39.64 |
| Resistance Level | $29.75 | $41.45 |
| Average True Range (ATR) | 1.05 | 0.84 |
| MACD | 0.21 | 0.24 |
| Stochastic Oscillator | 96.19 | 88.92 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About DCOM Dime Community Bancshares Inc.
Dime Commercial Bancshares Inc is the holding company for Dime Commercial Bank, a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island.